gefitinib has been researched along with Cancer of Stomach in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (56.67) | 29.6817 |
| 2010's | 9 (30.00) | 24.3611 |
| 2020's | 4 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, YS; Liu, J; Peng, Y; Xia, L; Yang, ZZ | 1 |
| Jadidi, A; Maadani, AM; Sardari, S; Shokrgozar, MA | 1 |
| An, JY; Bae, JM; Cho, HJ; Choi, MG; Her, NG; Hong, JY; Kang, WK; Kim, HJ; Kim, JS; Kim, JY; Kim, KM; Kim, M; Kim, S; Kim, ST; Koo, H; Lee, IK; Lee, J; Lee, JH; Lee, Y; Lim, HY; Nam, DH; Park, JO; Park, SH; Sa, JK; Seo, YJ; Shin, YJ; Sim, MH; Sohn, TS | 1 |
| Chen, Z; El-Rifai, W; Garcia-Buitrago, M; Khalafi, S; Lu, H; Peng, D; Poveda, J; Que, J; Soutto, M; Zaika, A; Zhu, S | 1 |
| Du, J; Han, Y; Lu, H; Sun, Q; Wang, L; Wei, X; Zhang, H; Zhang, R; Zheng, J; Zhou, W | 1 |
| Hu, C; Li, W; Ma, JA; Ren, J; Wei, Y; Zhou, D; Zhou, Y; Zou, F; Zou, W | 1 |
| Han, YF; Lin, X; Wu, LQ; Zhang, QY; Zhang, T | 1 |
| Jia, Y; Sun, T; Xiao, D | 1 |
| Kubo, T; Morimoto, K; Sato, Y; Seyama, T; Yanagihara, K | 1 |
| Bang, YJ; Han, SW; Hur, HS; Im, SA; Kim, HP; Kim, TY; Oh, DY; Yoon, YK | 1 |
| Teng, KY; Xu, RH | 1 |
| Belkhiri, A; El-Rifai, W; Zhu, S | 1 |
| Hasegawa, T; Hirakawa, K; Matsuzaki, T; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Chen, LQ; Gao, Q; Wang, KN; Wang, WP | 1 |
| Adelstein, DJ; Ives, DI; Phillips, BE; Plesec, T; Rice, TW; Rodriguez, CP; Rybicki, LA; Saxton, JP; Tubbs, RR; Videtic, GM | 1 |
| Blanco, Cdel V; Caputo, R; Ciardiello, F; Manzo, BA; Ricci, V; Romano, M; Tortora, G; Tuccillo, C; Zarrilli, R | 1 |
| Kang, JH; Kuh, HJ; Lee, SH; Nishio, K; Park, JK; Saijo, N | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Kishida, O; Kiyohara, T; Miyazaki, T; Miyazaki, Y; Murayama, Y; Ogasa, M; Shimomura, I; Shinomura, Y; Tsutsui, S; Watabe, K; Yamamoto, T | 2 |
| Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M | 1 |
| Date, M; Fujise, K; Matsumoto, K; Nakamura, T; Namiki, T; Namiki, Y; Satoi, J; Tada, N; Yanagihara, K; Yashiro, M; Yoshida, H | 1 |
| Barnard, GF; Ishii, H; Mimori, K; Mori, M; Nagahara, H; Sudo, T; Yamashita, K | 1 |
| Becker, JC; Domschke, W; Muller-Tidow, C; Pohle, T; Serve, H | 1 |
| Becker, JC; Berdel, WE; Brandts, C; Domschke, W; Fujimori, T; Ilea, AM; Müller-Tidow, C; Pohle, T; Serve, H; Stolte, M; Tickenbrock, L; Tidow, N | 1 |
| Albanell, J; Baselga, J; Doi, T; Koizumi, W; Ohtsu, A; Ramon Cajal, S; Ramon y Cajal, S; Rojo, F; Shirao, K; Tabernero, J; Takiuchi, H; Van Cutsem, E | 1 |
| Fujiwara, M; Ikehara, S; Ikehara, Y; Kodera, Y; Koike, M; Mochizuki, Y; Nakanishi, H; Nakao, A; Tatematsu, M; Yatabe, Y; Yokoyama, H | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
| Arao, T; Fukuoka, K; Kimura, H; Komatsu, T; Nishio, K; Saijo, N; Sasaki, H; Takeda, M; Tamura, T; Yamada, Y; Yanagihara, K; Yokote, H | 1 |
| Cao, WG; Chen, XH; Ji, YB; Jin, YN; Li, H; Li, JF; Liu, BY; Ma, T | 1 |
2 review(s) available for gefitinib and Cancer of Stomach
| Article | Year |
|---|---|
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Stomach Neoplasms; Trastuzumab | 2006 |
2 trial(s) available for gefitinib and Cancer of Stomach
| Article | Year |
|---|---|
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Cohort Studies; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab; Treatment Outcome | 2013 |
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Area Under Curve; Biomarkers, Tumor; Carcinoma; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Stomach Neoplasms | 2006 |
26 other study(ies) available for gefitinib and Cancer of Stomach
| Article | Year |
|---|---|
Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report.
Topics: Adenocarcinoma of Lung; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Stomach Neoplasms | 2021 |
Gefitinib-loaded polydopamine-coated hollow mesoporous silica nanoparticle for gastric cancer application.
Topics: Doxorubicin; Drug Carriers; Gefitinib; Humans; Nanoparticles; Porosity; Silicon Dioxide; Stomach Neoplasms | 2022 |
Comprehensive pharmacogenomic characterization of gastric cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Mutation; Pharmacogenomic Variants; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Stomach Neoplasms; Transcriptome; Tumor Cells, Cultured; Wnt Signaling Pathway | 2020 |
Silencing of miR490-3p by H. pylori activates DARPP-32 and induces resistance to gefitinib.
Topics: Animals; Cell Line, Tumor; DNA Methylation; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Resistance, Neoplasm; Gefitinib; Helicobacter Infections; Helicobacter pylori; Humans; Mice; Mice, Inbred C57BL; MicroRNAs; Receptor, Muscarinic M2; Stomach Neoplasms | 2020 |
Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; RNAi Therapeutics; Stomach Neoplasms | 2018 |
Downregulation of c-Met expression does not enhance the sensitivity of gastric cancer cell line MKN-45 to gefitinib.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Down-Regulation; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibitory Concentration 50; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; RNA Interference; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Transfection | 2015 |
Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases 1/2.
Topics: Adenocarcinoma; Antineoplastic Agents; Autophagy; Cell Survival; Cytoplasm; Enzyme Activation; Extracellular Fluid; Gefitinib; HMGB1 Protein; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor for Advanced Glycation End Products; RNA Interference; RNA, Small Interfering; Stomach Neoplasms; Transfection | 2015 |
Interference of STAT 5b expression enhances the chemo-sensitivity of gastric cancer cells to gefitinib by promoting mitochondrial pathway-mediated cell apoptosis.
Topics: Aged; Aged, 80 and over; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; STAT5 Transcription Factor; Stomach Neoplasms | 2015 |
High mannose-binding Pseudomonas fluorescens lectin (PFL) downregulates cell surface integrin/EGFR and induces autophagy in gastric cancer cells.
Topics: Animals; Autophagy; Cell Line, Tumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Integrins; Mannose-Binding Lectin; Mice; Pseudomonas fluorescens; Quinazolines; RNA, Small Interfering; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; In Situ Nick-End Labeling; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Stomach Neoplasms | 2009 |
DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms | 2011 |
An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
Topics: Animals; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Irinotecan; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Stomach Neoplasms | 2011 |
Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Stomach Neoplasms; Survival Rate | 2012 |
Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism.
Topics: Bacterial Proteins; Cyclooxygenase 2; ErbB Receptors; Gefitinib; Helicobacter pylori; Humans; Isoenzymes; MAP Kinase Signaling System; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Quinazolines; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Up-Regulation; Vascular Endothelial Growth Factor A | 2003 |
Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Base Pair Mismatch; Carrier Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Repair; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Fluorouracil; Formazans; G1 Phase; G2 Phase; Gefitinib; Gene Expression; Humans; Inhibitory Concentration 50; Models, Biological; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Stomach Neoplasms; Tetrazolium Salts | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Amphiregulin; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; EGF Family of Proteins; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Phosphorylation; Quinazolines; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; Transforming Growth Factor alpha; Tyrosine | 2005 |
Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Adenocarcinoma; Amphiregulin; Antineoplastic Agents; Camptothecin; EGF Family of Proteins; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Metalloproteases; Phosphorylation; Quinazolines; Reactive Oxygen Species; Stomach Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2005 |
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms | 2005 |
Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer.
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Adult; Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Cytokines; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Genetic Therapy; Hepatocyte Growth Factor; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Peritoneum; Quinazolines; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers.
Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Female; Gefitinib; Genes, erbB-1; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Stomach Neoplasms | 2006 |
Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Blotting, Western; Cell Survival; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Humans; Middle Aged; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Liver Neoplasms; Male; Mice; Mice, Nude; Neoplasms, Experimental; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2006 |
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2007 |
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dimerization; Gefitinib; Humans; Mice; Mice, Inbred Strains; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; RNA, Small Interfering; Stomach Neoplasms; Up-Regulation; Xenograft Model Antitumor Assays | 2007 |
[Effect of gefitinib on radiosensitivity of gastric cancer cell lines].
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Particle Accelerators; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Stomach Neoplasms | 2007 |